Rifaximin trial for alcohol-related liver disease
361 gut metagenome samples from adults in Denmark, part of the GALA-RIF trial, a randomized double-blind placebo-controlled phase 2 study of rifaximin-α in alcohol-related liver disease diagnosed by liver biopsy. machine-written summary
361 samples · 722 runs · DK · Adult · 2024 · 7.31 Gbp / sample · cohort Alcohol-related liver disease disrupts bile acid h
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 1,083 sample values (country, subject id, timepoint) |
| ✓ Abstract / description | 361 sample values (health condition detail) |
| – Full text | no open-access full text linked |
| – Supplementary tables | no supplementary tables available (or none open access) |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention — arms not resolved
design randomized_controlled_trial · Rifaximin-α vs placebo in alcohol-related liver disease, phase 2 trial
longitudinal
125 of 135 people sampled more than once (351 samples; median 3, up to 3 per person) · follow-up median 17 mo (max 17 mo) · median interval between samples 17 mo (time from timepoint labels). Schedule stated by the source: “Subjects sampled at baseline (BL), 1 month (1M), and 18 months (18M) post-intervention”.
Each row is one person (1 shown of 125); dots are samples at days since that person's first sample.
Genera, mean relative abundance over 320 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 361 | 100% | ||||
| country | 361 | 100% | 361 | |||
| health_condition | 0 | 0% | ||||
| subject_id | 361 | 100% | 361 | |||
| health_condition_detail | 361 | 100% | 361 | |||
| timepoint_label | 361 | 100% | 361 |
- Alcohol-related liver disease disrupts bile acid homeostasis and gut microbial bile acid metabolism. 2026 PMID 41935631 PMC13233754 unsure
Archive description
The GALA-RIF trial, an investigator-initiated, randomized, double-blind, placebo-controlled, single-center, phase 2 study, was conducted to evaluate the efficacy of rifaximin-α in patients diagnosed with alcohol-related liver disease through liver biopsy
How this project entered the registry
Classified as human gut / stool / blood / tissue / internal fluids shotgun DNA metagenome of adult by deterministic_prior with confidence 0.90. Assay shotgun_dna.
- host external_curation.infant_catalog · “infant triage reason_code age_adult_only”
- body site study.title · “Metagenomics of the gut microbiome of individuals”
- body site study.description · “diagnosed with alcohol-related liver disease through liver”
- life stage external_curation.infant_catalog · “infant triage reason_code age_adult_only”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMEA115779112 | country | DK | R1 | 0.90 | sample.attr.geographic_location_country_and_or_sea | Denmark |
| SAMEA115779112 | health_condition_detail | mixed_case_control: ALD patients vs healthy controls | R4 | 0.50 | paper.abstract | ALD cohort (n = 462), alongside matched healthy controls |
| SAMEA115779112 | subject_id | EUKIP | R1 | 0.70 | sample.name_rule:title | GALA-RIF_EUKIP-BL |
| SAMEA115779112 | timepoint_label | BL | R1 | 0.70 | sample.name_rule:title | GALA-RIF_EUKIP-BL |
Sequencing
722 runs over 361 samples · mean 3.77 Gbp per run (median 2.89 Gbp, total 2,723.04 Gbp; 722 runs with a base count) · layout PAIRED 361, SINGLE 361 · platform ILLUMINA 722 · models Illumina HiSeq 4000 (722) · 81% of runs with a Sandpiper profile · first public 2024-11-12 – 2026-04-17
Authors (25)
Keller MI first · de Zawadzki A · Thiele M · Suvitaival T · Sulek K · Kuhn M · Schudoma C · Podlesny D · Nishijima S · Fullam A · Kim CY · Niu L · Wretlind A · Hansen JK · Israelsen M · Johansen S · Akanni W · Hazenbrink D · Juel HB · Mann M · Hansen T · Krag A · Bork P · Legido-Quigley C · GALAXY & MicrobLiver consortia last
Downloads
PRJEB76667.csv.gz (10.7 KB) · parquet (82.8 KB) — all 361 samples, every field with route and confidence · PRJEB76667_determinations.csv.gz (12.0 KB) — 1,444 evidence rows